USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ARGOLYN BIOSCIENCE, INC.
Address: ARGOLYN BIOSCIENCE, INC.
2750 Speissegger Drive, Suite 110
NORTH CHARLESTON, SC
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: (843) 266-0851

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $163,945.00 1
STTR Phase I $264,745.00 2
STTR Phase II $1,345,456.00 1

Award List:

NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: MEDICAL UNIVERSITY OF SOUTH CAROLINA
Principal Investigator: Thomas A. Dix
Award Amount: $125,279.00
RI Contact: N/A
Abstract:
Argolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-natural amino acid analogues for arginine (Arg) or lysine (Lys). In proof-of concept studies thus… More

NOVEL NEUROTENSIN ANALOGS AS ANTISCHIZOPRENICS

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: MEDICAL UNIVERSITY OF SOUTH CAROLINA
Principal Investigator: Thomas A. Dix
Award Amount: $139,466.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The brain peptide neurotensin (NT) and its active derivative NT [8-13] function as endogenous neuroleptics. Stable NT derivatives that cross the blood brain barrier therefore have significant potential for development as a new class of non-dopamineric… More

Novel Neurotensin Analogs as Antischizophrenics

Award Year / Program / Phase: 2005 / STTR / Phase II
Agency: HHS
Research Institution: N/A
Principal Investigator: Thomas A. Dix
Award Amount: $1,345,456.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Low levels of the brain peptide neurotensin (NT) have been linked to schizophrenia. Hence, stable NT receptor agonists that cross the blood brain barrier have significant potential for development as a new class of antipsychotics that may not have the adverse… More

Development of Neurotensin-based Analgesics

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas A. Dix
Award Amount: $163,945.00
Abstract:
DESCRIPTION (provided by applicant): Chronic, neuropathic pain is one of the most important unmet medical needs in the United States, affecting tens to hundreds of millions of people nationwide at some time during their lives. Novel therapeutic approaches are desperately needed. The brain peptides… More